Biomarkers for the Phenotyping and Monitoring of Asthma in Children

被引：4
作者：
James A. [1 ]
Hedlin G. [2 ]
机构：
[1] Institute of Environmental Medicine, Karolinska Institutet, Stockholm
[2] Department of Women’s and Children’s Health and Centre for Allergy Research, Karolinska Institutet, Astrid Lindgren Children’s Hospital, Stockholm
来源：
Current Treatment Options in Allergy | 2016年 / 3卷 / 4期
关键词：
Airway inflammation markers; Allergy diagnosis; Biomarkers; Children; Phenotyping asthma;
D O I：
10.1007/s40521-016-0106-0
中图分类号：
学科分类号：
摘要：
An important issue in relation to the utility and reliability of biomarkers for asthma monitoring is how asthma is defined and characterized. What kind of asthma, or at what stage of the disease is a particular biomarker supposed to add information? Often, the purpose, or usefulness of a biomarker is not made clear. Diagnosis, severity evaluation, and monitoring are all different clinical uses for a biomarker, and confusion may arise when a biomarker is suitable for one of these but not another. When the utility of available biomarkers are discussed, these different roles need to be clarified. Our opinion is that there are four aspects of relevance to asthma, for which biomarkers are required: to diagnose allergies, to evaluate inflammation in the airways, to evaluate hyper-responsiveness, and for certain measures of lung function, such as lung clearance index. These types of biomarkers are needed for the phenotyping and monitoring of asthma. Another important role for biomarkers is, as mentioned above, to monitor asthma in order to follow treatment effects on inflammation and hyper-responsiveness as objective adjuncts to the patients’ own symptom reports and lung function. This review will mainly focus on biomarkers that reflect airway inflammation. In spite of the numerous studies that have been conducted, we still have to remember that the value of biomarkers available for routine use, such as eosinophil counts in blood and sputum and exhaled nitric oxide, have to be interpreted in relation to reported symptoms and lung function. Measures of bronchial hyper-responsiveness, performed either by direct (methacholine challenge) or indirect (exercise or mannitol challenge) methods, could be considered biomarkers but will not be included in this review. On the other hand, diagnosing allergy is not usually useful for monitoring asthma although it is of fundamental importance for the interpretation of most biomarkers that are suitable for monitoring. We have therefore included the different approaches for diagnosing and evaluating allergic sensitization in this review. © 2016, The Author(s).
引用
收藏
页码：439 / 452
页数：13
相关论文
共 98 条
[1]  
Newacheck P.W., Halfon N., Prevalence, impact, and trends in childhood disability due to asthma, Arch Pediatr Adolesc Med, 154, 3, pp. 287-293, (2000)
[2]  
Mallola J., Crane J., von Mutius E., Odhiambo J., Keil U., Stewart A., The International Study of Asthma and Allergies in Childhood (ISAAC) phase three: a global synthesis, Allergol Immunopathol (Madr), 41, 2, pp. 73-85, (2013)
[3]  
Fajt M.L., Wenzel S.E., Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care, J Allergy Clin Immunol, 135, pp. 299-310, (2015)
[4]  
Global strategy for asthma management and prevention
[5]  
Buchvald F., Bisgaard H., FeNO measured at fixed exhalation flow rate during controlled tidal breathing in children from the age of 2 yr, Am J Respir Crit Care Med, 163, 3, pp. 699-704, (2001)
[6]  
Covar R.A., Szefler S.J., Martin R.J., Sundstrom D.A., Silkoff P.E., Murphy J., Young D.A., Spahn J.D., Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma, J Pediatr, 142, pp. 469-475, (2003)
[7]  
Silkoff P.E., McClean P., Spino M., Erlich L., Slutsky A.S., Zamel N., Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients, Chest, 119, pp. 1322-1328, (2001)
[8]  
Dweik R.A., Sorkness R.L., Wenzel S., Et al., Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma, Am J Respir Crit Care Med, 181, pp. 1033-1041, (2010)
[9]  
Dweik R.A., Boggs P.B., Erzurum S.C., Irvin C.G., Leigh M.W., Lundberg J.O., Olin A.C., Plummer A.L., Taylor D.R., An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications, Am J Respir Crit Care Med, 184, 5, pp. 602-615, (2011)
[10]  
Petsky H.L., Cates C.J., Lasserson T.J., Et al., A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils), Thorax, 67, pp. 199-208, (2012)
12345678910